0
Skip to Content
The TruScreen Device
HPV Test Kits
Clinical Performance
Development History
Eliminating Cervical Cancer
Markets
Our People
Investors
Contact
News
Open Menu
Close Menu
The TruScreen Device
HPV Test Kits
Clinical Performance
Development History
Eliminating Cervical Cancer
Markets
Our People
Investors
Contact
News
Open Menu
Close Menu
The TruScreen Device
HPV Test Kits
Clinical Performance
Development History
Eliminating Cervical Cancer
Markets
Our People
Investors
Contact
News
Truscreen Priority Allocation of $1 Million Closed
4 June
Written By
NZX - OFFER
Previous
Previous
Truscreen Capital Change Notice
Next
Next
Results Announcement Date – Reliance on NZX Class Waiver